Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Thieme

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
British Journal of Clinical Pharmacology|October 1, 1988
Pharmacokinetics of mifentidine after single and multiple oral administration to healthy volunteersB P Imbimbo, R Urso, G Thieme, et al.
Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine|August 1, 1985
Diagnostic ultrasonography: certain legal considerationsA E James, A C Fleischer, G Thieme, et al.
Acta Medica Scandinavica|April 1, 1970
Oral L-dopa treatment of parkinsonismN E Andén, A Carlsson, J Kerstell, et al.
Zeitschrift Fur Arztliche Fortbildung|June 1, 1979
[Contribution to the clinical diagnosis of trisomy 21 on the basis of analysis of variance and discriminance]H Bach, I Bräunlich, E Freese, et al.
Plos Genetics|July 26, 2018
Velvet domain protein VosA represses the zinc cluster transcription factor SclB regulatory network for Aspergillus nidulans asexual development, oxidative stress response and secondary metabolismKarl G Thieme, Jennifer Gerke, Christoph Sasse, et al.
Plos Genetics|August 30, 2018
Correction: Velvet domain protein VosA represses the zinc cluster transcription factor SclB regulatory network for Aspergillus nidulans asexual development, oxidative stress response and secondary metabolismKarl G Thieme, Jennifer Gerke, Christoph Sasse, et al.
Life Science Alliance|November 11, 2025
The VelB IDD promotes selective heterodimer formation of velvet proteins for fungal developmentAnna M Köhler, Sabine Thieme, Jennifer Gerke, et al.
Ebiomedicine|December 24, 2025
Brain atrophy staging in spinocerebellar ataxia type 3 for clinical prognosis and trial enrichmentHannah Baumeister, Philipp Wegner, Mónica Ferreira, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
British Journal of Clinical Pharmacology|October 1, 1988
Pharmacokinetics of mifentidine after single and multiple oral administration to healthy volunteersB P Imbimbo, R Urso, G Thieme, et al.
Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine|August 1, 1985
Diagnostic ultrasonography: certain legal considerationsA E James, A C Fleischer, G Thieme, et al.
Acta Medica Scandinavica|April 1, 1970
Oral L-dopa treatment of parkinsonismN E Andén, A Carlsson, J Kerstell, et al.
Zeitschrift Fur Arztliche Fortbildung|June 1, 1979
[Contribution to the clinical diagnosis of trisomy 21 on the basis of analysis of variance and discriminance]H Bach, I Bräunlich, E Freese, et al.
Plos Genetics|July 26, 2018
Velvet domain protein VosA represses the zinc cluster transcription factor SclB regulatory network for Aspergillus nidulans asexual development, oxidative stress response and secondary metabolismKarl G Thieme, Jennifer Gerke, Christoph Sasse, et al.
Plos Genetics|August 30, 2018
Correction: Velvet domain protein VosA represses the zinc cluster transcription factor SclB regulatory network for Aspergillus nidulans asexual development, oxidative stress response and secondary metabolismKarl G Thieme, Jennifer Gerke, Christoph Sasse, et al.
Life Science Alliance|November 11, 2025
The VelB IDD promotes selective heterodimer formation of velvet proteins for fungal developmentAnna M Köhler, Sabine Thieme, Jennifer Gerke, et al.
Ebiomedicine|December 24, 2025
Brain atrophy staging in spinocerebellar ataxia type 3 for clinical prognosis and trial enrichmentHannah Baumeister, Philipp Wegner, Mónica Ferreira, et al.
Pageof 3